Newswire (Published: Tuesday, February 19, 2019, Received: Tuesday, February 19, 2019, 7:55:13 PM CST)

Word Count: 531

2019 FEB 19 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Drug Daily -- Researchers detail new data in Oncology - Prostate Cancer. According to news reporting out of Rochester, Minnesota, by NewsRx editors, research stated, “To report outcomes of patients undergoing low-dose-rate (LDR) brachytherapy and investigate factors associated with biochemical failure and survival. Consecutive patients undergoing LDR with I-125 at our institution between 1998 through 2013 for primary intact prostate cancer were examined.”

Our news journalists obtained a quote from the research from Mayo Clinic, “Those with low- and intermediate-risk disease receiving LDR with a minimum of 2 years followup and at least one post-LDR prostate-specific antigen (PSA) were included. About 974 patients satisfied inclusion criteria. With median followup of 72 months, biochemical failure occurred in 45 patients. Freedom from biochemical failure as defined by the Phoenix criterion was 96% and 88% at 5 and 10 years, worse for intermediate risk as compared with low risk, with 10-year freedom from biochemical failure of 76% versus 92% (hazard ratio [HR] = 3.7, p < 0.001), respectively. On multivariable analysis, increased prebiopsy PSA, Gleason 4 + 3, and no androgen deprivation therapy were associated with biochemical failure. Gleason 4 + 3 was the factor most strongly associated with biochemical failure (HR = 7.01, p < 0.001). No examined factors were associated with local failure. Gleason 4 + 3 disease increased the likelihood of distant metastasis (HR = 12.4, p = 0.003) and prostate cancer-specific death (HR = 13.2, p < 0.001). No difference in outcomes between patients with Gleason 3 + 3 versus 3 + 4 was observed. LDR brachytherapy provided excellent outcomes in this large series of patients treated for localized organ-confined prostate cancer. Local recurrence at 10 years was low at 2.1%. Primary Gleason 4 + 3, higher pretreatment PSA, and no receipt of androgen deprivation therapy were the only factors associated with biochemical failure.”

According to the news editors, the research concluded: “Primary Gleason 4 disease was also predictive of distant metastases and decreased prostate cancer-specific survival.”

For more information on this research see: Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients. Brachytherapy, 2019;18(1):1-7. Brachytherapy can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier - www.elsevier.com; Brachytherapy - http://www.journals.elsevier.com/brachytherapy/)

Our news journalists report that additional information may be obtained by contacting B.J. Davis, Mayo Clinic, Dept. of Radiat Oncol, 200 First St SW, Rochester, MN 55905, United States. Additional authors for this research include D.M. Routman, R.K. Funk, B.J. Stish, C.L. Deufel, K.M. Furutani, M.G. Haddock, T.M. Pisansky, C.R. Choo, L.A. Mynderse, T.M. Wilson, R. McLaren, W.S. Harmsen and K. Mara.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.brachy.2018.09.003. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Mayo Clinic

Places

North America
United States
Americas
Arizona
Minnesota
New York
Phoenix
Rochester
New York City

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies